Birju Mehta

2.0k total citations · 1 hit paper
17 papers, 683 citations indexed

About

Birju Mehta is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Birju Mehta has authored 17 papers receiving a total of 683 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Birju Mehta's work include CAR-T cell therapy research (15 papers), Immune Cell Function and Interaction (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Birju Mehta is often cited by papers focused on CAR-T cell therapy research (15 papers), Immune Cell Function and Interaction (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Birju Mehta collaborates with scholars based in United States and Germany. Birju Mehta's co-authors include Malcolm K. Brenner, Huimin Zhang, Helen E. Heslop, Bambi Grilley, Cliona M. Rooney, Haruko Tashiro, Olga Dakhova, Gianpietro Dotti, Zhuyong Mei and Nadia Mahmood and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Birju Mehta

15 papers receiving 678 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

2017 391 citations Andras Heczey, Chrystal U. Louis et al. Molecular Therapy profile →

Peers

Countries citing papers authored by Birju Mehta

Since Specialization

Citations

This map shows the geographic impact of Birju Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birju Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birju Mehta more than expected).

Fields of papers citing papers by Birju Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birju Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birju Mehta. The network helps show where Birju Mehta may publish in the future.

Co-authorship network of co-authors of Birju Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Birju Mehta. A scholar is included among the top collaborators of Birju Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birju Mehta. Birju Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL) 2023 ·Hematological Oncology ·Carlos A. Ramos, David H. Quach, Premal Lulla, Rayne H. Rouce, Sandhya Sharma, (unknown), Nazila Nouraee, (unknown), (unknown), Sachin G. Thakkar, Birju Mehta, (unknown), Emily M. Hsieh, Huimin Zhang, Bambi Grilley, Natalia Lapteva, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney	8
2	Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas 2023 ·Blood ·LaQuisa Hill, Rayne H. Rouce, Meng-Fen Wu, Tao Wang, Royce Ma, Huimin Zhang, Birju Mehta, Natalia Lapteva, Zhuyong Mei, Tyler S. Smith, Lina Yang, Madhuwanti Srinivasan, (unknown), Carlos A. Ramos, Premal Lulla, (unknown), Bambi Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin	30
3	Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy 2023 ·Journal for ImmunoTherapy of Cancer ·Sandhya Sharma, Mae Woods, (unknown), Tim Sauer, Kathan Parikh, Michael Schmueck‐Henneresse, Huimin Zhang, Birju Mehta, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney	8
4	Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL. 2023 ·Journal of Clinical Oncology ·LaQuisa Hill, Rayne H. Rouce, Tyler S. Smith, (unknown), Madhuwanti Srinivasan, Sachin G. Thakkar, Huimin Zhang, Birju Mehta, (unknown), Bambi Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin	7
5	Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies 2022 ·Molecular Therapy ·Norihiro Watanabe, Feiyan Mo, Rong Zheng, Royce Ma, (unknown), Dayenne G. van Leeuwen, (unknown), Hongxiang Hu, Sha Wang, Birju Mehta, Madhuwanti Srinivasan, (unknown), Huimin Zhang, Sachin G. Thakkar, LaQuisa Hill, Helen E. Heslop, Chonghui Cheng, Malcolm K. Brenner, Maksim Mamonkin	45
6	CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma 2022 ·Blood ·David H. Quach, Carlos A. Ramos, Premal Lulla, Sandhya Sharma, (unknown), Nazila Nouraee, (unknown), (unknown), (unknown), Sachin G. Thakkar, Birju Mehta, (unknown), Emily M. Hsieh, Huimin Zhang, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Rayne H. Rouce, Natalia Lapteva, Cliona M. Rooney	17
7	Phase I Trial of GD2.CAR T Cells Combined with a Novel Interleukin-7 Signal Modulator 2022 ·Transplantation and Cellular Therapy ·Bilal Omer, Thomas Shum, Jennifer Foster, Kathan Parikh, (unknown), (unknown), (unknown), Birju Mehta, Huimin Zhang, Sachin G. Thakkar, Swati Naik, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney	0
8	Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma 2021 ·Blood ·Rayne H. Rouce, LaQuisa Hill, Tyler S. Smith, Lina Yang, (unknown), Madhuwanti Srinivasan, Huimin Zhang, (unknown), Birju Mehta, Olga Dakhova, Bambi Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin	14
9	Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma 2021 ·Blood ·David H. Quach, Carlos A. Ramos, Premal Lulla, Sandhya Sharma, (unknown), (unknown), Sachin G. Thakkar, (unknown), Birju Mehta, (unknown), Eric C. Anderson, Emily M. Hsieh, Olga Dakhova, Huimin Zhang, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Rayne H. Rouce, Natalia Lapteva, Cliona M. Rooney	6
10	CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity 2020 ·Biology of Blood and Marrow Transplantation ·LaQuisa Hill, Rayne H. Rouce, Tyler S. Smith, Lina Yang, Madhuwanti Srinivasan, Huimin Zhang, (unknown), Birju Mehta, Olga Dakhova, (unknown), Bambi Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin	17
11	A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma 2020 ·Blood ·David H. Quach, (unknown), Sachin G. Thakkar, (unknown), Birju Mehta, (unknown), Eric Anderson, Emily M. Hsieh, Olga Dakhova, Huimin Zhang, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Carlos A. Ramos, Rayne H. Rouce, Natalia Lapteva, Cliona M. Rooney	5
12	Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies 2019 ·Blood ·LaQuisa Hill, Rayne H. Rouce, Tyler S. Smith, Lina Yang, Madhuwanti Srinivasan, Huimin Zhang, (unknown), Birju Mehta, Olga Dakhova, (unknown), Bambi Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin	51
13	Use of highly characterized EBV-Specific T Cells outside of the immediate Post-Transplant setting 2019 ·Cytotherapy ·Rayne H. Rouce, (unknown), Sandhya Sharma, Nirav R. Shah, (unknown), Carlos A. Ramos, Natalia Lapteva, Huimin Zhang, Birju Mehta, (unknown), Mary K. McKenna, Adrian P. Gee, Premal Lulla, John D. Castello, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney	2
14	Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells 2017 ·Clinical Cancer Research ·Miyuki Tanaka, Haruko Tashiro, Bilal Omer, (unknown), Jun Ando, Minhtran Ngo, Birju Mehta, Gianpietro Dotti, Paul R. Kinchington, Ann M. Leen, Claudia Rössig, Cliona M. Rooney	81
15	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma breakdown → 2017 ·Molecular Therapy ·Andras Heczey, Chrystal U. Louis, Barbara Savoldo, Olga Dakhova, April Durett, Bambi Grilley, Hao Liu, (unknown), Zhuyong Mei, Adrian P. Gee, Birju Mehta, Huimin Zhang, Nadia Mahmood, Haruko Tashiro, Helen E. Heslop, Gianpietro Dotti, Cliona M. Rooney, Malcolm K. Brenner	391
16	Use of highly characterized EBV-specific T cells for treatment of EBV+ lymphoma outside of the HSCT setting 2017 ·Cytotherapy ·Rayne H. Rouce, Nirav R. Shah, (unknown), Sandhya Sharma, (unknown), Huimin Zhang, Birju Mehta, Premal Lulla, Sai Ravi Pingali, Natalia Lapteva, Adrian P. Gee, Ann M. Leen, Helen E. Heslop, Cliona M. Rooney	1
17	Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma 2016 ·Blood ·Rayne H. Rouce, Birju Mehta, Sandhya Sharma, Serena Perna, Benjamin J. Shin, Vicky Torrano, (unknown), Natalia Lapteva, Catherine M. Bollard, Adrian P. Gee, Carlos A. Ramos, (unknown), (unknown), Kurt C. Gunter, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact